Incorporating Monoclonal Antibodies into the First-Line Treatment of Classical Hodgkin Lymphoma

Incorporating Monoclonal Antibodies into the First-Line Treatment of Classical Hodgkin Lymphoma

The long-term survival of Hodgkin lymphoma (HL) patients treated according to the current standard of care is excellent. Combined-modality schedules (ABVD plus radiotherapy) in early-stage disease, along with treatment intensity adaptation to early metabolic response assessed by PET/CT in advanced s...

Full description

Bibliographic Details
Main Authors: Theodoros P. Vassilakopoulos, Athanasios Liaskas, Patricio Pereyra, Panayiotis Panayiotidis, Maria K. Angelopoulou, Andrea Gallamini
Format: Article
Language:English
Published: MDPI AG 2023-08-01
Series:International Journal of Molecular Sciences
Subjects:
Hodgkin lymphoma
novel agents
first-line treatment
brentuximab vedotin
nivolumab
pembrolizumab
Online Access:https://www.mdpi.com/1422-0067/24/17/13187

Internet

https://www.mdpi.com/1422-0067/24/17/13187

Similar Items